FDA Panel Endorses Capivasertib Use in Prostate Cancer

An FDA advisory panel voted 7-1, with one abstention, to endorse the use of capivasertib (Truqap) for the treatment of an aggressive subtype of prostate cancer. The Oncologic Drugs Advisory Committee's favorable recommendation signals that full FDA approval may follow in the coming months. Capivasertib is an AKT pathway inhibitor previously approved for breast cancer, and its potential expansion into prostate cancer represents a meaningful new treatment option for patients with limited alternatives. The strong vote margin suggests confidence in the drug's efficacy and safety data in this new indication.